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Aim: The present study was designed to test the cellular uptake of PEGylated liposomes 
targeted to transferrin receptor and to α-synuclein by a cell model of the blood–brain 
barrier (BBB). Materials & methods: PEGylated immunoliposomes were prepared with 
anti-transferrin receptor OX26 and anti-α-synuclein LB509 antibodies to overcome 
the BBB in Parkinson’s disease. Results: The doubly targeted immunoliposomes 
bind to transferrin receptor and to α-synuclein protein, as assessed by ELISA assays. 
We establish that 40% of an encapsulated tested drug (epigallocatechin-3-gallate) 
is released in a time frame of 44 h, which is reasonable for sustained release. The 
cellular uptake of doubly targeted immunoliposomes in cultured brain endothelial 
cells hCMEC/D3 was two-times more efficient than that of PEGylated liposomes. 
Conclusion: Immunoliposomes targeted to BBB receptors and to α-synuclein could 
potentially enable the transport of drugs across the BBB and reach one of the drug 
targets in Parkinson’s disease.
Lay abstract: The blood–brain barrier (BBB) prevents the distribution of drugs into 
the brain, making the development of new treatments for brain disorders such as 
Parkinson’s disease difficult. This is due to the presence of tight cell–cell junctions 
within the brain capillary endothelium. Nanocarriers that transport drugs across the 
BBB enable noninvasive modes of drug delivery (e.g., oral, systemic routes) to the 
brain. In the present study, we developed vesicles targeted with antibodies to BBB 
receptors and to a biological target of Parkinson’s disease. This technology, known as 
Trojan horse technology, uses endogenous molecules that are able to cross the BBB 
through receptors present in the brain capillary endothelium.
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Parkinson’s disease (PD), a neurodegen-
erative disorder for which there is no cure, 
affects nearly seven million people world-
wide. Clinically, the disease evolves from 
subtle nonspecific nonmotor manifestations 
to advanced stages with severe motor (dys-
kinesias and rigidity) and cognitive impair-
ments [1,2]. The pathological hallmarks of the 
disease are characterized by a prominent loss 
of dopamine-producing neurons in the sub-
stantia nigra (SN), which causes dopamine 
reduction in the striatum and the presence 
of neuronal cytoplasmic inclusions known 
as Lewy bodies [3]. Since Lewy bodies are 
rich in aggregated α-synuclein, this protein 
is proposed to be a key factor in the patho-
genesis of PD [4]. α-synuclein is a natively 
unordered, soluble protein that spontane-
ously self-assembles into insoluble aggregates 
or amyloid fibrils [5]. The conformational 
changes of the protein lead to the formation 
of insoluble neurotoxic aggregates [6,7]. The 
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inhibition of α-synuclein aggregation has become a 
valid therapeutic target in PD.
For noninvasive administration, drugs developed 
for the treatment of PD or other neurodegenerative 
disorders need to cross the blood–brain barrier (BBB). 
This barrier is the cerebral microvascular endothelium, 
which has tight cell–cell junctions and few alternate 
transport pathways (e.g., decreased pinocytotic activ-
ity and significantly decreased number of intracellular 
fenestrae). The targeting of liposomes across the BBB 
with receptor-specific peptidomimetic monoclonal 
antibodies (MAbs) is a known technology that enables 
the delivery of drugs noninvasively to the brain [8]. The 
drugs can be encapsulated in the interior of liposomes 
that are targeted to the BBB receptors with MAbs. 
This approach allows higher carrying capacities of the 
MAbs than the individually conjugation of drugs to 
MAbs.
We prepared PEGylated liposomes doubly targeted 
with the OX26MAb to the rat transferrin receptor 
and the LB509MAb to the α-synuclein. The flavo-
noid epigallocatechin-3-gallate (EGCG) was encapsu-
lated in the interior of the liposomes as a model drug. 
EGCG is a natural antioxidant capable of inhibiting 
α-synuclein toxicity [9]. It inhibits the protein aggrega-
tion and the α-synuclein oligomers’ ability of inducing 
cytotoxicity in brain cells [9,10]. The EGCG bioavail-
ability is low, only 0.1% after administration of tea 
polyphenols, and its systemic clearance is high, render-
ing EGCG use for the treatment of CNS disorders very 
limited [11]. Although the BBB targeting with MAbs 
against endogenous BBB receptors is a well-studied 
technology [12], the use of two different MAbs to target 
liposomes to the brain is less developed. The present 
study was designed to test the cellular uptake of doubly 
targeted PEGylated liposomes to transferrin receptor 
and to α-synuclein by a cell model of the BBB.
Materials & methods
Formulation of liposomes
All lipids were purchased from Avanti Polar Lip-
ids. The liposomes were prepared by the lipid film 
hydration method. DSPC (1,2-distearoyl-sn-glycero-
3-phosphocholine), Chol (cholesterol ovine wool), 
DSPE-PEG
2000
 (1,2-distearoyl-sn-glycero-3-phospho-
ethanolamine-N-[amino(polyethylene glycol)-2000] 
ammonium salt), DSPE-PEG
2000
-maleimide 
(1,2-distearoyl-sn-glycero-3-phosphoethanolamine-
N-[maleimide(polyethylene glycol)-2000] ammonium 
salt), DSPE-PEG
2000
-biotin (1,2-distearoyl-sn-glycero-
3-phosphoethanolamine-N-[biotin(polyethylene 
glycol)-2000] ammonium salt) and LissRhod-PE 
(1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine-
N-(lissamine rhodamine B sulfonyl) ammonium salt, 
Avanti Polar Lipids) were dissolved in chloroform at 
a molar ratio of 52:45:3:0.015:0.015:0.01. The sol-
vent was evaporated using a nitrogen stream in a 
rotary evaporator and the resultant dried lipid film 
was dispersed in PBS buffer, pH 7.4 (phosphate buff-
ered saline, 10 mM phosphate buffer, 2.7 mM potas-
sium chloride and 137 mM sodium chloride, Sigma-
Aldrich) with a final total lipid concentration of 0.80 
mM. The liposome suspension was vortexed, frozen-
thawed and then extruded through polycarbonate fil-
ters with pore diameters of 100 nm and 50 nm at least 
ten-times using a Mini Extruder (Avanti Polar Lipids). 
The fluorescence intensity of each type of liposomes 
was measured with a Synergy 2 Multi-Mode Micro-
plate Reader (BioTek Instruments Inc., with excitation 
filter 528/20 nm and emission filter 580/50 nm) and 
the concentration adjusted to the same value.
Conjugation of antibodies
The MAb against the transferrin BBB receptor 
(OX26MAb) was obtained from AbD Serotec and the 
MAb against α-synuclein (LB509MAb) was purchased 
from Abcam. Covalent coupling methods for attaching 
the antibodies at the PEG terminus were based on func-
tionalized PEG with a chemically reactive end-group, 
the PEG-maleimide (thiol reactive) and a PEG-biotin 
(the biotin–streptavidin method). For the maleimide-
MAb conjugation, the MAb was activated by a 20-times 
molar excess of Traut’s reagent (2-iminothiolane hydro-
chloride, Sigma-Aldrich). A drop of EDTA (ethylene-
diaminetetraacetic acid, Sigma-Aldrich) 0.28 M was 
added to prevent metal-catalyzed oxidation of sulf-
hydryl groups [13]. The unreacted complex EDTA/2-
iminothiolane was removed by size exclusion chroma-
tography using a Sephadex column PD-Mini Trap G25 
(GE Healthcare) [14]. It has been previously shown that 
thiolation of MAb does not interfere with their binding 
site [15]. Since the maleimide group slowly hydrolyzes in 
aqueous solution, it is essential to perform the antibody 
conjugation immediately after the preparation of the 
liposomes. The second MAb was first coupled to a bio-
tin molecule using the EZ-Link microsulfo-NHS-LC-
biotin (Thermo Scientific) kit. The MAb was linked 
to the functionalized PEG-biotin through streptavidin 
(from Streptomyces avidinii, Sigma-Aldrich) at a molar 
ratio of 1:1. Both antibodies were added to the lipo-
somes at a molar ratio of 1:1 between antibodies and 
functionalized PEG. The liposomes and the antibodies 
were incubated at room temperature (RT) for 1 h and 
then at 5°C for 8 h.
Liposome characterization
The hydrodynamic diameter and zeta potential of 
the liposomes were analyzed using a Zetasizer Nano 
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ZS (Malvern Instruments Ltd.). Size measurements 
are based on photon correlation spectroscopy and 
zeta potential is based on laser Doppler velocimetry. 
PEGylated liposomes were also characterized by cryo-
scanning electron microscopy (cryo-SEM) using a 
JEOL JSM 6301F/Oxford INCA Energy 350. The 
images were acquired with a Gatan Alto 2500.
Enzyme-linked immunosorbent assay for 
immunoliposomes
The functional activity of the antibodies conjugated 
to the liposomes was analyzed by the enzyme-linked 
immunosorbent assay (ELISA). The surface of 96-well 
plates (flat-bottom Nunc MaxiSorp®) was coated with 
either transferrin receptor (Abcam) or α-synuclein for 
1 h at 37°C. After blocking with bovine serum albu-
min (BSA), the immunoliposomes were added to each 
well, followed by a washing step. The secondary anti-
body conjugated with peroxidase (Goat anti-Mouse 
IgG [H+L] Cross Adsorbed Secondary Antibody, HRP 
conjugate, Thermo Scientific-Pierce Antibodies) was 
then allowed to react for 45 min at RT. To reveal the 
presence of the antibodies, a citrate solution was used 
with citric acid (Sigma-Aldrich), ABTS (2,2′-azino-
bis(3-ethylbenzothiazoline-6-sulfonic acid) diam-
monium salt, Sigma-Aldrich) and H
2
O
2
 (hydrogen 
peroxide solution, Sigma-Aldrich). The color intensity 
was measured by spectrometry using a spectrometer 
(Synergy 2 Multi-Mode Microplate Reader, BioTek 
Instruments Inc.). Liposomes without MAb were used 
as control. The statistical significance was determined 
by Student’s t-test analysis.
Catechin encapsulation & release
The loading of liposomes with EGCG (458 Da, Taiyo 
Kaguku) was performed during the hydration step of 
the lipid film. The dried lipid film was hydrated with 
an aqueous solution containing the catechin at molar 
ratios of 16:1 and 10:1 (phospholipid:peptide). Non-
encapsulated catechin was removed by using a Sepha-
dex column PD-Midi Trap G25. For the determina-
tion of the encapsulation efficiency, the liposomes were 
burst with water:ethanol 25:75 (v/v) and the absorp-
tion spectrum was measured (Synergy 2 Multi-Mode 
Microplate Reader, BioTek Instruments Inc.). The 
encapsulation efficiency was calculated based on the 
encapsulated fraction and the total EGCG added. The 
release of EGCG from the liposomes was studied by 
using a dialysis bag (Float-A-Lyzer G2, CE, 100 kDa, 
SpectrumLabs). A volume of 2 ml of immunolipo-
somes was added into the dialysis tube and dialysis was 
carried out against buffer at 37°C with continuously 
stirring (200 rpm). Aliquots from the medium out-
side the dialysis bag were collected at different times. 
The amount of catechin released from the liposomes 
was determined by the absorbance at 274 nm. The 
percentage of the released EGCG at each time point, 
(Catechin)
t
, is then calculated from Equation 1:
where (Catechin)
total
 is the concentration of catechin 
added initially to the lipid film.
Cellular uptake & cytotoxicity assays
Immortalized human cerebral microvascular endo-
thelial cell line (hCMEC/D3) was incubated at 37°C 
in complete medium (Fetal Bovine Serum ‘Gold’ 5% 
[PAA, The Cell Culture Company], penicillin/strep-
tomycin 1% [Penicillin, 10,000 units; Streptomy-
cin, 10,000 μg/ml – Invitrogen, Gibco], hydrocorti-
sone 1.4 μM [Sigma-Aldrich], acid ascorbic 5 μg/ml 
[Sigma-Aldrich], chemically defined lipid concentrate 
1/100 [Invitrogen, Gibco], HEPES 10 mM [PAA, 
The Cell Culture Company], human basic fibro-
blast growth factor 1 ng/ml [bFGF, Sigma-Aldrich] 
and endothelial basal medium [EBM-2, Lonza]) in a 
96-well plate (Corning) previously coated with Cul-
trex® Rat Collagen I (R&D Systems, Trevigen). The 
culture medium was replaced at every 48 h incubation 
time. Normally, apparent confluence of the monolayers 
was reached after 6 days (≈6–8 × 104 cells per well). At 
day 6, the medium was replaced by a solution of Krebs 
Table 1. Mean diameter, polydispersity index and zeta potential of immunoliposomes.
Liposome formulation Mean diameter (nm) PDI Zeta potential (mV)
PEGylated liposomes 86 ± 1 0.14 ± 0.01 0.2 ± 0.4
LB 509MAb-PEGylated liposomes 98 ± 3 0.17 ± 0.01 -1.8 ± 0.2
OX26MAb-PEGylated liposomes 104 ± 4 0.19 ± 0.01 -1.5 ± 0.1
OX26MAb-/LB509MAb-PEGylated liposomes 105 ± 6 0.21 ± 0.01 -2.8 ± 0.3
Values given as mean ± standard deviation.
The tip of some of the PEG molecules was conjugated to anti-α-synuclein monoclonal antibody (LB 509MAb), anti-transferrin receptor 
antibody (OX26MAb) or to both antibodies. Error bars represent standard deviations over three replicas.
PDI: Polydispersity index; PEG: Polyethylene glycol.
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Ringer buffer (KRB) containing different concentra-
tions of the immunoliposomes. KRB is composed by 
NaCl (sodium chloride p.A., AppliChem), KCl (potas-
sium chloride, AppliChem), H
2
KO
4
P (potassium 
dihydrogen phosphate p.A., AppliChem), HEPES 
(hepes puffedran ≥99.5% p.A., ROTH),  d -Glucose 
( d (+)-glucose anhydrous for biochemistry, MERCK), 
MgCl
2
·6H
2
O (magnesium chloride hexahydrate p.A., 
AppliChem) and CaCl
2
·2H
2
O (calcium chloride dehy-
drate p.A., AppliChem). The cells were incubated with 
the immunoliposomes at 37°C for 2 and 6 h. After 
removal of the suspension by aspiration, the cells were 
rinsed at 4°C: three-times with medium, then with a 
buffer pH 3 (26 mM of sodium citrate, Sigma; 9.2 mM 
citric acid monohydrated, Grussing; 90.1 mM NaCl 
and 30 mM KCl) for 5 min followed by KRB. The 
supernatants were discarded and the cells were lysed 
with a Triton X-100 1% solution for 1 h at 65°C. The 
fluorescence intensity was measured with a Synergy 2 
Multi-Mode Microplate Reader (BioTek Instruments 
Inc., with excitation filter 528/20 nm and emission fil-
ter 580/50 nm). The initial concentration of liposomes 
was determined by fluorescence and was within the 
linear range of detection of the method.
For the cytotoxicity assays, the immunoliposomes 
were incubated with the cells for 2 h at 37°C. Cells 
without liposomes and lysed cells by 1% Triton were 
used as negative and positive controls, respectively. 
After removal of the immunoliposomes suspension or 
medium (controls) by aspiration, the cells were incu-
bated with Alamar Blue reagent 40:1 (water:Alamar 
Blue – v/v) (Thermo Scientific) up to 4 h. The fluo-
rescence was detected with a Synergy 2 Multi-Mode 
Microplate Reader (BioTek Instruments Inc., excita-
tion 528/20 nm and emission 580/50 nm).
Student’s t-test statistical analysis was used to deter-
mine statistical significance between cells exposed to 
PEGylated liposomes (control) and cells exposed to 
antibody-decorated PEGylated liposomes. A p-value of 
less than 0.05 was considered statistically significant.
Results & discussion
Liposome formulations
We prepared the following systems: A) PEGylated 
liposomes without antibodies (control); B) PEGylated 
liposomes with anti-α-synuclein antibody LB509MAb 
coupled through maleimide; C) PEGylated liposomes 
with anti-transferrin receptor antibody OX26MAb 
coupled through streptavidin-biotin system; and D) 
PEGylated liposomes with both OX26MAb and 
LB509MAb (OX26MAb-/LB509MAb-PEGylated 
liposomes).
The hydrodynamic diameter of the liposomes ranges 
between 86 nm (control liposomes) and 105 nm (lipo-
somes with antibodies) (Table 1 and Figure 1). These 
results are in accordance with the size observed by 
cryo-SEM for PEGylated liposomes. The images 
show spherical liposomes with an average diameter 
of approximately 100 nm (Figure 2). The variations 
of the diameter observed for immunoliposomes are 
related to the size of the antibodies and bioconjugate 
reagent. The hydrodynamic diameter of immunolipo-
somes coupled to LB509MAb (formulation B) is about 
12  nm larger than that of the control liposomes, which 
is approximately the diameter of globular MAbs. For 
the formulation C and D, the diameter is 18–19 nm 
Figure 1. Physical stability of immunoliposomes. 
Variation of the hydrodynamic diameter (black 
symbols) and the zeta potential (blue open symbols) 
of liposomes over 3 months: PEGylated liposomes (▪), 
PEGylated liposomes with anti-α-synuclein antibody 
LB509MAb (•), PEGylated liposomes with anti-
transferrin receptor antibody OX26MAb (triangle) and 
PEGylated liposomes with OX26MAb and LB509MAb 
(♦). Error bars are standard deviations of mean (n = 3).
Figure 2. Cryo-scanning electron micrograph of 
PEGylated liposomes.
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larger, which might account for the streptavidin-biotin 
system and MAbs. The addition of MAbs to the lipo-
somes does not significantly affect their zeta potential, 
even if a small variation to negative values is observed 
(Table 1).
The size and zeta potential of the immunoliposomes 
were measured for 3 months to assess their physical sta-
bility (Figure 1). There were no significant variations on 
these parameters, which indicate that the immunolipo-
somes are stable at least over 3 months [16]. Since aggre-
gation could decrease the cellular uptake efficiency of 
the immunoliposomes, it is important to monitor their 
properties over time. We did not observe aggregation 
of any of the formulations and all liposomes had a 
diameter around 100 nm.
Binding of OX26MAb-/LB509MAb-PEGylated 
liposomes to target proteins
The ability of the antibody-decorated liposomes to con-
tinue to recognize their ligands was assessed by ELISA. 
First, each ligand (transferrin receptor, α-synuclein or 
PBS as a control) was adsorbed to the bottom surface of 
96-well plates, and then incubated with the respective 
immunoliposomes (formulations B, C and D) or with 
PEGylated liposomes (A) as control; finally, to assess the 
formation of the ligand-antibody binding, a secondary 
antibody was used to reveal the presence or absence of 
immunoliposomes. Control liposomes (A) showed an 
absorbance at 405 nm of around 0.30 in all the wells 
with different types of coating (Figure 3). Immunolipo-
somes with LB509MAb (liposomes B) gave an increase 
in the absorbance in the wells coated with α-synuclein 
(0.73 ± 0.04). Immunoliposomes coupled to OX26MAb 
(liposomes C) had higher absorbance in the wells 
coated with transferrin receptor (0.69 ± 0.03). Impor-
tantly, the immunoliposomes coupled to both MAbs 
(liposomes D) showed functionality for both ligands 
as concluded by the absorbance at 405 nm of 0.71 ± 
0.04 and 0.70 ± 0.02, when testing against α-synuclein 
and transferrin receptor, respectively (Figure 3). We did 
not observe nonspecific binding of immunoliposomes 
to α-synuclein or transferrin receptor. The MAbs are 
unmodified and thus they interact with a single target, 
as they are specific for a single epitope of an antigen. The 
OX26MAb-/LB509MAb-PEGylated liposomes show 
similar activity in terms of binding to the two different 
targets, transferrin receptor and α-synuclein.
Catechin release from OX26MAb-/LB509MAb-
PEGylated liposomes
The encapsulation efficiency of EGCG was about 76 ± 
7%. The size, solubility, composition and biodegrada-
tion of the liposome are the main factors that affect 
the release rate of a drug [17]. Besides, a time compro-
mise for the drug release profile is needed. If the cate-
chin-loaded liposomes are too stable, the drug release 
will not occur but if the drug is not well entrapped, 
it will leak prematurely. We studied the release profile 
Figure 3. Binding affinity. Binding of immunoliposomes 
to target proteins α-synuclein and transferrin receptor 
assessed by ELISA. A: PEGylated liposomes; B: PEGylated 
liposomes with anti-α-synuclein antibody LB509MAb; 
C: PEGylated liposomes with anti-transferrin receptor 
antibody OX26MAb; D: PEGylated liposomes with 
OX26MAb and LB509MAb. Phosphate saline buffer was 
used as a control. Error bars are standard deviations of 
mean (n = 3).  
*Statistically significant from A in each group 
(p < 0.001).
Figure 4. In vitro epigallocatechin-3-gallate release 
profile from immunoliposomes. The liposomes 
are coupled with anti-transferrin receptor 
antibody OX26MAb and anti-α-synuclein antibody 
LB509MAb and the drug release was studied 
using dialysis membranes (molecular weight 
cutoff: 100 kDa; dark cyan squares). The permeation of 
nonencapsulated drug through the membrane is shown 
as a control (black circles). Error bars are standard 
deviations of mean (n = 3). 
EGCG: Epigallocatechin-3-gallate.
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of EGCG from immunoliposomes (with the two anti-
bodies) using the dialysis method in PBS (pH 7.4) at 
4 and 37°C. The release profile of the catechin from 
the immunoliposomes showed a regular pattern with 
a continuous release. At 37°C, EGCG was released 
from the liposomes during the first 12 h in a percent-
age of approximately 25% (Figure 4). After 44 h, the 
release of EGCG reached a percentage of cumulative 
release of about 40%, indicating a sustained release. 
The presence of the two antibodies on the surface of 
the PEGylated liposomes does not prevent the release 
of the tested drug.
In vitro uptake & cytotoxicity of OX26MAb-/
LB509MAb-PEGylated liposomes
The immortalized hCMEC/D3 cell line has been 
demonstrated to mimic the endogenous microvascu-
lar brain endothelial cells due to expression of tight 
junction proteins [18–21]. The cells were incubated 
with the liposomes for 2 and 6 h at 37°C. The rela-
tive uptake efficiency corresponds to the amount of 
liposomes in cells divided by the initial concentration 
of liposomes.
The uptake of control liposomes (PEGylated lipo-
somes with no antibody attached – formulation A) 
and liposomes with anti-α-synuclein antibody (for-
mulation B) by hCMEC/D3 at concentrations of 60 
μM is comparatively much lower than the uptake of 
liposomes with OX26MAb (C) and liposomes with 
the two antibodies (D) (Figure 5). The uptake ratios 
at 60 μM were 5.9% for formulation A, 4.3% for B, 
10% for C and 13% for D. The results indicate that 
OX26MAb increases the uptake efficiency of lipo-
somes by the BBB cell model. As the immunolipo-
some concentration increases, the cellular uptake per-
centage decreases, which indicates a saturable uptake 
mechanism. The cellular uptake of liposomes after 
6 h incubation time at 37°C shows similar trend as 
the incubation for 2 h.
The cytotoxicity of the liposomes was assessed by 
using the Alamar Blue assay, which measures quan-
titatively the proliferation of cell lines. The results 
demonstrate that all different liposome formula-
tions in the concentration range of 60–200 μM are 
not toxic to hCMEC/D3 cells (Figure 6). The safety 
of nanocarriers is crucial for their use in clinics and 
should be considered in all steps of drug develop-
ment studies. Previous studies report that the weekly 
administration of PEGylated immunoliposomes to 
rats does not cause toxic effects, no inflammation in 
the brain [22].
The results of this study support the following 
conclusions. The conjugation of the MAb against 
the α-synuclein to OX26MAb-decorated liposomes 
does not alter their cellular uptake by the BBB cell 
model hCMEC/D3. The OX26MAb-/LB509MAb-
PEGylated liposomes show similar cellular uptake 
efficiency as OX26MAb-PEGylated liposomes. The 
cellular uptake efficiency (ratio of internal fluores-
cence compared with total fluorescence) decreases 
with the increasing of the concentration of immuno-
liposomes, which might indicate a saturable uptake 
mechanism. Increasing the incubation time has little 
effect on the cellular uptake efficiency at any of the 
concentrations tested, likely due to exocytosis of the 
immunoliposomes.
The presence of receptor-mediated transport 
(RMT) system within the BBB, such as the transfer-
rin receptor, enables the use of an endogenous peptide 
or peptidomimetic MAb that is able to cross the BBB 
via a specific RMT system (molecular Trojan horse 
Figure 5. Cellular uptake of liposomes in hCMEC/D3 
cells as a function of concentration and of incubation 
time. (i) 2 h and (ii) 6 h. A: PEGylated liposomes; B: 
PEGylated liposomes with anti-α-synuclein antibody 
LB509MAb; C: PEGylated liposomes with anti-
transferrin receptor antibody OX26MAb; D: PEGylated 
liposomes with OX26MAb and LB509MAb. The uptake 
is measured as mean fluorescence. The concentration 
relates to the phospholipid content. Error bars are 
standard deviations of mean values (n = 3).  
*p < 0.04.
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technology) [23]. MAbs are preferable over the endog-
enous peptides because the plasma concentration of 
the latter is high leading to a saturation of the protein 
binding sites on the BBB receptor. MAbs bind to epi-
topes on the BBB receptor that are removed from the 
endogenous ligand. The conjugation of PEGylated 
liposomes to antibodies against the transferrin recep-
tor for in vivo brain targeting of drugs was proposed 
almost two decades ago [24]. An important property 
of these systems is their ability to transcytose through 
the BBB. The MAb against transferrin receptors used 
here, the OX26MAb to the rat transferrin receptor, 
was shown to traverse the BBB by a similar mecha-
nism that mediates the BBB transcytosis of endoge-
nous transferrin [25,26]. Importantly, OX26MAb-dec-
orated liposomes were found to undergo transcytosis 
across monolayers of immortalized RBE4 rat brain 
endothelial cells [27]. Another study had established 
that the uptake and transcytosis of liposomes func-
tionalized with OX26MAb by hCMEC/D3 cells are 
higher than those of the liposomes without MAb [28]. 
The study had also indicated that the uptake 
mechanism of OX26MAb-decorated liposomes is 
receptor-mediated.
The development of liposomes with dual-tar-
geting properties enables noninvasive delivery of 
drugs to areas of the brain affected by a particular 
disease [8]. One ligand enables the transport of lipo-
somes through the BBB and a second ligand allows 
the binding of the system to the drug target. This 
strategy is currently being explored in Alzheimer’s 
disease research studies [29–31]. Immunoliposomes 
with two different ligands, one to target the BBB 
and a second to target the amyloid beta-peptide 
(main component of Alzheimer’s disease plaques), 
have been reported [14,32–33]. PEGylated immunoli-
posomes doubly targeted with MAbs had also been 
reported to deliver RNAi expression plasmid for the 
treatment of brain cancer [34]. This field needs more 
active research and developments in order to obtain 
optimized systems.
Conclusion
The present study demonstrates that OX26MAb-/
LB509MAb-PEGylated liposomes have affinity for 
both the ligands transferrin receptor and α-synuclein 
(neuronal protein that is linked to Parkinson’s disease) 
and that they are internalized by immortalized human 
cerebral microvascular endothelial cells. The drugs are 
encapsulated in the liposomes and the surface of the 
liposome is coated with PEG, which restricts the lipo-
some uptake by the reticuloendothelial system. The 
receptor-specific MAbs can then target the liposome 
across biological membranes.
Future perspective
Targeting nanocarriers to the brain with only one type 
of mAbs that target a singular antigen has limitations. 
Noninvasive delivery of drugs to the brain requires both 
their transcytosis through the BBB and their transport 
to the target site. At least two ligands are necessary for 
efficient drug targeting to the brain. The advances in 
this field will probably lead to even more complex sys-
tems with several ligands to target multicomponents. 
Liposomes are already in clinical use for the treatment 
of cancer and infectious diseases and the tendency will 
be to develop further the liposome technology to deliver 
therapeutics to the brain in neurodegenerative diseases. 
More studies are necessary to determine whether this 
strategy will become a standardized way of delivering 
drugs to the brain.
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Executive summary
• Immunoliposomes targeted to rat transferrin receptor with OX26 monoclonal antibody and to α-synuclein 
with LB509 monoclonal antibody are prepared.
• The doubly targeted immunoliposomes react with transferrin receptors and to α-synuclein with the same 
efficiency as the liposomes conjugated to only the respective single antibody.
• The cellular uptake efficiency of doubly targeted immunoliposomes by a model of the endothelial cells of 
the blood–brain barrier (hCMEC/D3 cell line) is comparable to the liposomes targeted only to transferrin 
receptors.
• The immunoliposomes do not show cytotoxicity at the concentrations tested (up to 200 μM).
• The increase of the immunoliposome concentration in the cellular uptake studies indicates a saturable 
mechanism, which is consistent with a receptor-mediated uptake mechanism.
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